S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:VCELVericel Stock Price, Forecast & News

$15.34
-0.31 (-1.98 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.23
Now: $15.34
$15.62
50-Day Range
$13.03
MA: $15.58
$17.19
52-Week Range
$6.78
Now: $15.34
$19.57
Volume13,011 shs
Average Volume692,500 shs
Market Capitalization$694.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.99
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Read More
Vericel logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCEL
CUSIPN/A
Phone617-588-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.85 million
Cash Flow$0.20 per share
Book Value$2.49 per share

Profitability

Miscellaneous

Employees216
Market Cap$694.14 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$15.34
-0.31 (-1.98 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vericel (NASDAQ:VCEL) Frequently Asked Questions

How has Vericel's stock been impacted by Coronavirus?

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VCEL stock has increased by 27.0% and is now trading at $15.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vericel?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vericel
.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Vericel
.

How were Vericel's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) issued its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The biotechnology company earned $20 million during the quarter, compared to analyst estimates of $19.31 million. The business's quarterly revenue was down 23.7% on a year-over-year basis. During the same period last year, the firm earned ($0.05) EPS.
View Vericel's earnings history
.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million.

What price target have analysts set for VCEL?

5 Wall Street analysts have issued twelve-month price objectives for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Vericel
.

Has Vericel been receiving favorable news coverage?

Headlines about VCEL stock have trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Vericel
.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), Amarin (AMRN), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX) and Verastem (VSTM).

Who are Vericel's key executives?

Vericel's management team includes the following people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
  • Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.51%), Vanguard Group Inc. (5.26%), Fort Washington Investment Advisors Inc. OH (1.55%), GW&K Investment Management LLC (1.47%), New York State Common Retirement Fund (1.30%) and Summit Creek Advisors LLC (1.05%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman.
View institutional ownership trends for Vericel
.

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, RTW Investments LP, Emerald Advisers LLC, Marshall Wace LLP, Silvercrest Asset Management Group LLC, Vanguard Group Inc., GW&K Investment Management LLC, and Falcon Point Capital LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin.
View insider buying and selling activity for Vericel
.

Which institutional investors are buying Vericel stock?

VCEL stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Summit Creek Advisors LLC, Prosight Management LP, Cadence Capital Management LLC, Goldman Sachs Group Inc., WINTON GROUP Ltd, Conestoga Capital Advisors LLC, and Rafferty Asset Management LLC.
View insider buying and selling activity for Vericel
.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $15.34.

How big of a company is Vericel?

Vericel has a market capitalization of $694.14 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

What is Vericel's official website?

The official website for Vericel is www.vcel.com.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.